Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.

MLA

Haworth, Kellie B., et al. “Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.” Pediatric Blood & Cancer, vol. 63, no. 4, Apr. 2016, pp. 618–26. EBSCOhost, https://doi.org/10.1002/pbc.25842.

APA

Haworth, K. B., Arnold, M. A., Pierson, C. R., Leddon, J. L., Kurmashev, D. K., Swain, H. M., Hutzen, B. J., Roberts, R. D., & Cripe, T. P. (2016). Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials. Pediatric Blood & Cancer, 63(4), 618–626. https://doi.org/10.1002/pbc.25842

Chicago

Haworth, Kellie B, Michael A Arnold, Christopher R Pierson, Jennifer L Leddon, Dias K Kurmashev, Hayley M Swain, Brian J Hutzen, Ryan D Roberts, and Timothy P Cripe. 2016. “Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.” Pediatric Blood & Cancer 63 (4): 618–26. doi:10.1002/pbc.25842.